MA31666B1 - Cyclic peptide cxcr4 antagonists - Google Patents

Cyclic peptide cxcr4 antagonists

Info

Publication number
MA31666B1
MA31666B1 MA32439A MA32439A MA31666B1 MA 31666 B1 MA31666 B1 MA 31666B1 MA 32439 A MA32439 A MA 32439A MA 32439 A MA32439 A MA 32439A MA 31666 B1 MA31666 B1 MA 31666B1
Authority
MA
Morocco
Prior art keywords
cxcr4 peptide
periodic anti
periodic
cxcr4
peptide
Prior art date
Application number
MA32439A
Other languages
Arabic (ar)
English (en)
Inventor
Wayne David Kohn
Sheng-Bin Peng
Liang Zeng Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31666(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA31666B1 publication Critical patent/MA31666B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des antagonistes cxcr4 de peptides cyclisés par lactame, utiles dans le traitement des cancers, de la polyarthrite rhumatoïde, de la fibrose pulmonaire et de l'infection au vih.
MA32439A 2007-05-30 2009-12-21 Cyclic peptide cxcr4 antagonists MA31666B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US94099607P 2007-05-31 2007-05-31
PCT/US2008/064177 WO2008150689A1 (fr) 2007-05-30 2008-05-20 Antagonistes cxcr4 de peptides cycliques

Publications (1)

Publication Number Publication Date
MA31666B1 true MA31666B1 (fr) 2010-09-01

Family

ID=39831600

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32439A MA31666B1 (fr) 2007-05-30 2009-12-21 Cyclic peptide cxcr4 antagonists

Country Status (33)

Country Link
US (3) US7691813B2 (fr)
EP (2) EP2160221B1 (fr)
JP (1) JP5358564B2 (fr)
KR (2) KR101319740B1 (fr)
CN (1) CN101678213B (fr)
AR (1) AR066648A1 (fr)
AT (1) ATE516853T1 (fr)
AU (1) AU2008260326B2 (fr)
BR (1) BRPI0812134A2 (fr)
CA (1) CA2688574C (fr)
CL (1) CL2008001467A1 (fr)
CO (1) CO6241137A2 (fr)
CR (1) CR11105A (fr)
CY (1) CY1111815T1 (fr)
DK (1) DK2160221T3 (fr)
DO (1) DOP2009000270A (fr)
EA (1) EA017716B1 (fr)
GT (1) GT200900304A (fr)
HK (1) HK1141474A1 (fr)
HR (1) HRP20110551T1 (fr)
IL (1) IL201685A (fr)
JO (1) JO2776B1 (fr)
MA (1) MA31666B1 (fr)
MX (1) MX2009012952A (fr)
MY (1) MY149432A (fr)
NZ (1) NZ580849A (fr)
PE (1) PE20090299A1 (fr)
PL (1) PL2160221T3 (fr)
PT (1) PT2160221E (fr)
TN (1) TN2009000496A1 (fr)
TW (1) TWI423987B (fr)
WO (1) WO2008150689A1 (fr)
ZA (1) ZA200908345B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
WO2012118124A1 (fr) * 2011-03-01 2012-09-07 国立大学法人京都大学 Nouvel antagoniste de récepteur de chimiokines
AU2012266355B2 (en) * 2011-06-07 2016-06-09 Polyphor Ag Beta - hairpin peptidomimetics as CXC4 antagonists
CN104780930A (zh) * 2011-09-30 2015-07-15 程云 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
EP2771484A1 (fr) 2011-10-28 2014-09-03 Galderma Research & Development Nouveaux marqueurs d'infiltrat leucocytaire de rosacée et utilisations de ceux-ci
EP2979991A1 (fr) 2014-07-31 2016-02-03 Greif International Holding BV. Matériau multicouche, tapis de protection contre l'incendie avec ce matériau multicouche et ensemble de conteneur de transport et de stockage comprenant ledit tapis de protection contre l'incendie
EP3050574B1 (fr) 2015-01-28 2019-10-09 Universite De Bordeaux Utilisation de plerixafor pour le traitement et/ou la prévention des exacerbations aiguës de la bronchopneumopathie chronique obstructive
WO2017176565A1 (fr) 2016-04-07 2017-10-12 Eli Lilly And Company Combinaisons d'un anticorps anti-b7-h1 et d'un agoniste du peptide cxcr4 pour le traitement d'une tumeur solide
CN109922818B (zh) * 2016-09-06 2024-02-20 主线生物科学公司 Cxcr4拮抗剂及使用方法
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
WO2019050564A1 (fr) * 2017-09-05 2019-03-14 Mainline Biosciences Conjugué de liaison sélective à cxcr4 avec une affinité élevée et son procédé d'utilisation
US11123437B2 (en) * 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
WO2019126796A1 (fr) * 2017-12-21 2019-06-27 Mainline Biosciences Llc Composition comprenant un agent thérapeutique et un antagoniste sélectif du cxcr4, et ses procédés d'utilisation
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
AU2019338221B2 (en) 2018-09-12 2024-04-04 Technische Universität München CXCR4-targeted diagnostic and therapeutic agents with reduced species selectivity
WO2020053255A1 (fr) 2018-09-12 2020-03-19 Technische Universität München Agents thérapeutiques et diagnostiques pour le cancer
US20220218852A1 (en) * 2019-04-18 2022-07-14 Provincial Health Services Authority Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
JP2023516878A (ja) * 2020-01-26 2023-04-21 メインライン バイオサイエンシーズ（シャンハイ）シーオー．，エルティーディ． 同位体標識された選択的ｃｘｃｒ４結合性ペプチドコンジュゲート並びにその作製方法及び使用方法
US20240124517A1 (en) * 2020-12-25 2024-04-18 Chugai Seiyaku Kabushiki Kaisha Method for producing peptide compound containing n-substituted-amino acid residue
EP4043041A1 (fr) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands pour usage diagnostique et thérapeutique et leurs précurseurs
WO2023201435A1 (fr) * 2022-04-20 2023-10-26 Provincial Health Services Authority Composés ciblant cxcr4, et leurs procédés de fabrication et d'utilisation
CN115060901A (zh) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規ｃｘｃｒ４アンタゴニスト
EP1991562A2 (fr) 2006-02-27 2008-11-19 Technische Universität München Imagerie et traitement du cancer

Also Published As

Publication number Publication date
HRP20110551T1 (hr) 2011-09-30
BRPI0812134A2 (pt) 2014-11-18
KR20100003737A (ko) 2010-01-11
MX2009012952A (es) 2009-12-11
PE20090299A1 (es) 2009-03-19
JO2776B1 (en) 2014-03-15
EA017716B1 (ru) 2013-02-28
EP2160221A1 (fr) 2010-03-10
JP2010529957A (ja) 2010-09-02
CL2008001467A1 (es) 2008-12-05
AR066648A1 (es) 2009-09-02
US20080300177A1 (en) 2008-12-04
TW200902556A (en) 2009-01-16
CN101678213A (zh) 2010-03-24
CO6241137A2 (es) 2011-01-20
EA200971129A1 (ru) 2010-04-30
KR101319740B1 (ko) 2013-10-17
AU2008260326B2 (en) 2011-07-21
JP5358564B2 (ja) 2013-12-04
US20100130409A1 (en) 2010-05-27
CY1111815T1 (el) 2015-10-07
TWI423987B (zh) 2014-01-21
WO2008150689A1 (fr) 2008-12-11
CA2688574C (fr) 2014-02-18
DOP2009000270A (es) 2010-01-15
USRE42274E1 (en) 2011-04-05
PT2160221E (pt) 2011-09-12
GT200900304A (es) 2011-11-09
CN101678213B (zh) 2013-11-06
HK1141474A1 (en) 2010-11-12
IL201685A0 (en) 2010-05-31
ATE516853T1 (de) 2011-08-15
CA2688574A1 (fr) 2008-12-11
MY149432A (en) 2013-08-30
EP2377579A1 (fr) 2011-10-19
KR20110134519A (ko) 2011-12-14
ZA200908345B (en) 2011-02-23
DK2160221T3 (da) 2011-09-19
PL2160221T3 (pl) 2011-12-30
IL201685A (en) 2015-04-30
EP2160221B1 (fr) 2011-07-20
KR101169846B1 (ko) 2012-08-01
CR11105A (es) 2010-04-12
NZ580849A (en) 2012-03-30
US7691813B2 (en) 2010-04-06
AU2008260326A1 (en) 2008-12-11
TN2009000496A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
MA31666B1 (fr) Cyclic peptide cxcr4 antagonists
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
MXPA06003474A (es) Agonistas de receptores de melanocortina.
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
PE20120429A1 (es) Proteinas de enlace de miostatina
TR201909741T4 (tr) Kolon temizleme bileşimleri.
CY1113770T1 (el) Κυκλικα αντι-μικροβιακα πεπτιδια
PT1353689E (pt) Composicoes imunizantes e metodos de utilizacao
DE60230722D1 (de) Il-8-rezeptor-antagonisten
ATE398630T1 (de) Zyklische conotoxin-peptide
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
EA200600782A1 (ru) Терапевтические применения вариантов хемокинов
SE0302304D0 (sv) Novel compounds
ATE386050T1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
MA27474A1 (fr) Vaccin
WO2010057275A8 (fr) Peptides cycliques et leurs utilisations
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
EA200500533A1 (ru) Пептидные производные - ингибиторы слияния при вич-инфекции
ATE474046T1 (de) Vasopressin bindende l-nukleinsäure
FR2858234B1 (fr) Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers
EP2322559A3 (fr) Anticorps specifiques de neoplasme et utilisations associees
CY1106540T1 (el) Ετεροκυλικα υποκατεστημενες στη θεση 3 πιπεριδινο-2,6-διονες
UA99458C2 (ru) Циклопептидные антагонисты cxcr4